The role of dialysis in contrast-induced nephropathy: Doubts and certainties

Journal of Cardiovascular Medicine

Volumn 8, Issue 8, 2007, Pages 549-557

  Guastoni, Carlo ^a,c   De Servi, Stefano ^a   D'Amico, Marco ^b  

^a Civic Hospital   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c Ospedale Civile   (Italy)

Author keywords

Contrast media; Contrast induced nephropathy; Dialysis

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; BICARBONATE; CONTRAST MEDIUM; CUPROPHANE; DIATRIZOATE; FENOLDOPAM; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPENTOL; IOPROMIDE; IOTROLAN; IOVERSOL; IOXAGLIC ACID; IOXITALAMIC ACID; POLYSULFONE; THEOPHYLLINE;

BICARBONATE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTINUOUS INFUSION; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOADING DRUG DOSE; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERITONEAL DIALYSIS; POTASSIUM BLOOD LEVEL; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VASCULAR DISEASE;

CONTRAST MEDIA; DISEASE PROGRESSION; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; METABOLIC CLEARANCE RATE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR DISEASES;

EID: 34547702294     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000281709.43681.a5     Document Type: Review

References (59)

1. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003; 4 (Suppl 5):S3-S9.
2. Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004; 44:12-24.
3. Cox CD, Tsikouris JP. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol 2004; 44:327-337.
4. Berns AS. Nephrotoxicity of contrast media. Kidney Int 1989; 36:730-740.
5. Deray G. Nephrotoxicity of contrast media. Nephrol Dial Transplant 1999; 14:2602-2606.
6. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000; 36:679-684.
7. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000; 11:177-182.
8. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264.
9. Gruberg L, Mintz GS, Mehran R, Dangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36:1542-1548.
10. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39:1113-1119.
11. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95:13-19.
12. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44:1393-1399.
13. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med 1995; 332:647-655.
14. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999; 34:685-691.
15. Ide JM, Lancelot E, Pines E, Corot C. Prophylaxis of iodinated contrast media-induced nephropathy: a pharmacological point of view. Invest Radiol 2004; 39:155-170.
16. Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005; 20:1542-1550.
17. Heyman SN, Rosenberger C, Rosen S. Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol Dial Transplant 2005; 20 (Suppl 1):i6-i11.
18. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416-1420.
19. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329-336.
20. Mueller C, Seidensticker P, Buettner HJ, Perruchoud AP, Staub D, Christ A, et al. Incidence of contrast nephropathy in patients receiving comprehensive intravenous and oral hydration. Swiss Med Wkly 2005; 135:286-290.
21. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86 (Pt 1):649-652.
22. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004; 43:1-9.
23. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Elia P, et al. Standard vs. double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004; 25:206-211.
24. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004; 15:761-769.
25. Briguori C, Colombo A, Airoldi F, Morici N, Sangiorgi GM, Violante A, et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2005; 68:2250-2255.
26. Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W Jr, Vlietstra RE, et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000; 101:2172-2177.
27. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, for the Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491-499.
28. Erdogan A, Davidson CJ. Recent clinical trials of iodixanol. Rev Cardiovasc Med 2003; 4 (Suppl 5):S43-S50.
29. Sharma SK, Kini A. Effect of non-ionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. Catheter Cardiovasc Interv 2005; 65:386-393.
30. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005; 68:2256-2263.
31. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291:2328-2334.
32. Kini AA, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001; 2 (Suppl 1):S19-S25.
33. Kini AS, Mitre CA, Kamran M, Suleman J, Kim M, Duffy ME, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002; 89:999-1002.
34. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, et al., for the CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290:2284-2291.
35. Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003; 91:1157-1162.
36. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354:379-386.
37. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111:692-698.
38. Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kunzendorf U, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003; 60:176-182.
39. Karie S, Launay-Vacher V, Izzedine H, Deray G. Is dialysis efficient in the prevention of ionic contrast agent-induced nephropathy? Presse Med 2005; 34:803-808.
40. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349:1333-1340.
41. Giannattasio M. Contrast-induced acute renal failure. G Ital Nefrol 2005; 22:217-225.
42. Lorusso V, Taroni P, Alvino S, Spinazzi A. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis. Invest Radiol 2001; 36:309-316.
43. Gabutti L, Marone C, Monti M, Malfanti M, Zwahlen U, Pasotti E, et al. Does continuous venovenous hemodiafiltration concomitant with radiological procedures provide a significant and safe removal of the iodinated contrast ioversol? Blood Purif 2003; 21:152-157.
44. Matzkies FK, Reinecke H, Tombach B, Kosch M, Hegger K, Milius M, et al. Influence of dialysis procedure, membrane surface and membrane material on iopromide elimination in patients with reduced kidney function. Am J Nephrol 2000; 20:300-304.
45. Erley CM, Bader BD, Berger ED, Vochazer A, Jorzik JJ, Dietz K, et al. Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med 2001; 29:1544-1550.
46. Spinazzi A, Ceriati S, Pianezzola P, Lorusso V, Luzzani F, Fouillet X, et al. Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers. Invest Radiol 2000; 35:1-7.
47. Moon SS, Back SE, Kurkus J, Nilsson-Ehle P. Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. Nephron 1995; 70:430-437.
48. Schindler R, Stahl C, Venz S, Ludat K, Krause W, Frei U. Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 2001; 16:1471-1474.
49. Iawamoto M, Hiroshige K, Suda T, Ohta T, Othani A, Nakashima Y. Elimination of iomeprol in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1999; 19:380-385.
50. Lehnert T, Keller E, Gondolf K, Schaffner T, Pavenstadt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998; 13:358-362.
51. Huber W, Jeschke B, Kreymann B, Hennig M, Page M, Salmhofer H, et al. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol 2002; 37:471-481.
52. Kawashima S, Takano H, Iino Y, Takayama M, Takano T. Prophylactic hemodialysis does not prevent contrast-induced nephropathy after cardiac catheterization in patients with chronic renal insufficiency. Circ J 2006; 70:553-558.
53. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6:1451-1458.
54. Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006; 119:155-162.
55. Tadros GM, Herzog CA. Percutaneous coronary intervention in chronic kidney disease patients. J Nephrol 2004; 17:364-368.
56. Younathan CM, Kaude JV, Cook MD, Shaw GS, Peterson JC. Dialysis is not indicated immediately after administration of nonionic contrast agents in patients with end-stage renal disease treated by maintenance dialysis. AJR Am J Roentgenol 1994; 163:969-971.
57. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 2003; 76:513-518.
58. Thomsen HS, Morcos SK. Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines. Eur Radiol 2006; 16:1835-1840.
59. Sirken G, Raja R, Garces J, Bloom E, Fumo P. Contrast-induced translocational hyponatremia and hyperkalemia in advanced kidney disease. Am J Kidney Dis 2004; 43:e31-e35.